Brexit
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
CEO of New UK Cell And Gene Therapy Hub Says 'All Systems Are Go'
CEO of the Stevenage-based center hopes the new cell and gene manufacturing hub will see a growing life sciences ecosystem coalesce around it.
Sanofi Top UK Exec Plans For Hard Brexit, Blasts 'Poor Access' To New Drugs
The managing director for Sanofi in the UK says clinical trials there will become less likely in future if access to innovative drugs doesn't improve, causing comparative standards of care to deteriorate.
Latest From Brexit
Unease Mounts Over Brexit Drug Shortage Risk
Not enough is known about how industry is preparing for Brexit when it comes to drugs approved via Europe’s mutual recognition and decentralized procedures. National regulators are urging companies to get their house in order.
EMA To Discuss Reactivating Landmark Clinical Trials Transparency Policy
No-Deal Brexit Means ‘Re-Planning A Whole Industry,’ Says ABPI Chief
Mike Thompson, head of the Association of the British Pharmaceutical Industry, outlined his industry’s concerns over medicines stockpiling, batch testing, tariffs, regulatory collaboration and other issues at a parliamentary committee hearing on the implications of a no-deal Brexit.
QUOTED. Oct. 11, 2018. Jonathan Mogford.
Negotations over the UK's impending exit from the EU are heating up, but there is not enough focus on what needs to happen to get to a mutually beneficial agreement between the two parties, says a top official at the UK agency that regulates devices and. See part of what Jonathan Mogford had to say here.
Brexit: We Really Are Worth Keeping, Says Senior UK Regulator
Not enough is being said about how to get a positive outcome from Brexit and those interested in seeing a continued close regulatory partnership between the UK and the EU should make their voice heard, says Jonathan Mogford, policy director at the Medicines and Healthcare products Regulatory Agency.
Brexit: We Really Are Worth Keeping, Says Senior UK Regulator
Not enough is being said about how to get a positive outcome from Brexit and those interested in seeing a continued close regulatory partnership between the UK and the EU should make their voice heard, says Jonathan Mogford, policy director at the Medicines and Healthcare products Regulatory Agency.
UK MHRA No-Deal Proposal Must Be Carefully Managed, UK Medtech Industry Leader Warns
Questions still remain related to the recent technical notices and consultations from UK MHRA on the effects of a no-deal Brexit. Association of British Healthtech Industries' Phil Brown offers pointers as interested parties prepare to respond the consultations, which have a November 1 deadline.
Helping Hand: A Guide To The New UK Consultations On No-Deal Brexit Regs
With just over three weeks to provide input on the UK's proposed regulatory response to the prospect of a no-deal Brexit, Medtech Insight unravels key messages from the four documents issued by the Medicines and Healthcare products Regulatory Agency (MHRA), condensing 127 pages into the main points to aid industry in providing feedback. There's no time to waste for those wishing to influence the outcome.
MHRA Admits UK Medtechs Exposed To Risks As It Consults On Brexit No-Deal Impact
The UK Medicines and Healthcare products Regulatory Agency is now consulting, in detail, on what a no-deal Brexit could look like and how it would impact manufacturers and the MHRA itself. Companies have less than four weeks to respond.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.